Metropolis Healthcare · NSE: METROPOLIS · BSE: 542650
Q4 FY23 results · Jan–Mar 2023
Metropolis Healthcare reported revenue from operations of ₹282.55 crore (down 7.6% from Q4 FY22) and net profit of ₹33.49 crore (down 16.6% from Q4 FY22) for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 282.55 | 305.90 | −7.6% | 285.46 | −1.0% |
| Other income | 1.23 | 5.68 | −78.4% | 6.62 | −81.5% |
| Total income | 283.77 | 311.58 | −8.9% | 292.08 | −2.8% |
| Profit before tax | 41.90 | 56.47 | −25.8% | 47.97 | −12.7% |
| Net profit for the period | 33.49 | 40.15 | −16.6% | 35.86 | −6.6% |
| Attributable to shareholders of the company | 33.36 | 39.99 | −16.6% | 35.80 | −6.8% |
| EPS, basic (₹) | 6.50 | 7.81 | −16.7% | 6.99 | −6.9% |
| Net margin (%) | 11.9 | 13.1 | 12.6 |
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 264.41 | 261.05 | +1.3% | 264.55 | −0.1% |
| Other income | 9.14 | 5.73 | +59.5% | 6.79 | +34.6% |
| Total income | 273.54 | 266.78 | +2.5% | 271.35 | +0.8% |
| Profit before tax | 48.32 | 46.29 | +4.4% | 44.38 | +8.9% |
| Net profit for the period | 39.93 | 33.08 | +20.7% | 32.83 | +21.6% |
| EPS, basic (₹) | 7.80 | 6.47 | +20.6% | 6.41 | +21.7% |
| Net margin (%) | 15.1 | 12.7 | 12.4 |
Consolidated
- Filed with BSE
- 18 May 2023, 11:01 IST
- Board meeting
- 16 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 18 May 2023, 11:01 IST
- Board meeting
- 16 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE